AVALO THERAPEUTICS, INC. Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements
AVALO THERAPEUTICS, INC. (AVTX) reported Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements of 0 shares for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-18.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements · last filed 2019-03-18
- AVALO THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of equity unit purchase agreements for the quarter ending 2017-09-30 was 0.00 shares.
- AVALO THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of equity unit purchase agreements for the quarter ending 2016-09-30 was 0.00 shares.
- AVALO THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of equity unit purchase agreements for fiscal 2018 was 0.00 shares, a 100.00% decline from fiscal 2017.
- AVALO THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of equity unit purchase agreements for fiscal 2017 was 283.28K shares.
- AVALO THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of equity unit purchase agreements for fiscal 2016 was 0.00 shares.
- AVALO THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of equity unit purchase agreements for fiscal 2015 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements 3 month | Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements 9 month | Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements 12 month |
|---|---|---|---|
| 2018-12-31 | 0.00 shares 10-K · filed 2019-03-18 | ||
| 2017-12-31 | 283.28K shares 10-K · filed 2019-03-18 | ||
| 2017-09-30 | 0.00 shares 10-Q · filed 2017-11-07 | 0.00 shares 10-Q · filed 2017-11-07 | |
| 2016-12-31 | 0.00 shares 10-K · filed 2018-04-02 | ||
| 2016-09-30 | 0.00 shares 10-Q · filed 2017-11-07 | 0.00 shares 10-Q · filed 2017-11-07 | |
| 2015-12-31 | 0.00 shares 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |